Hero banner

    The Signal

    The Signal is Nasdaq’s editorial business news series, showcasing the leading companies that are moving markets. Episodes feature candid conversations with founders and CEOs across industries, unpacking the latest technologies, innovations, and applications that are driving change across the economy.

    THE SIGNAL VIDEO SERIES

    Featured Videos

    The Signal: Primmune Therapeutics
    Primmune Therapeutics is a clinical‑stage biotechnology company based in San Diego, California, focused on developing systemic cancer immunotherapies that activate the immune system in a precise and controlled way. In this episode, Charles (Charlie) McDermott, CEO & Director of Primmune Therapeutics, discusses the company’s mission to strengthen antitumor immunity, enhance the effectiveness of existing cancer treatments, and improve long‑term disease control by engaging both the innate and adaptive immune systems. Primmune’s approach is designed to generate durable immune responses against cancer - going beyond T‑cell activation alone. The company’s lead investigational program, PRTX007, is an orally administered small‑molecule TLR7 agonist engineered to drive coordinated immune activation. At the heart of Primmune’s work is the vision to bring powerful immunotherapies earlier in care and expand the opportunity to cure cancer for more patients worldwide.
    Apr 10, 2026
    1 / 7